Saber, Diversicare, Good Samaritan Clinical Leaders Share Hard-Won Strategies to Reduce Antipsychotic Use, Rehospitalizations
By
Amy Stulick
1d agoen
Source
skillednursingnews.comSaber, Diversicare, Good Samaritan Clinical Leaders Share Hard-Won Strategies to Reduce Antipsychotic Use, Rehospitalizationsskillednursingnews.comClinical success in the nursing home can be broken down into its parts – namely, performance on quality measures. And while QMs have expanded to account for a range of areas, reducing hospital readmissions and antipsychotic use remain top priorities for clinicians. There are some throughlines here, clinical leaders told Skilled Nursing News, with interdisciplinary […] The post Saber, Diversicare, Good Samaritan Clinical Leaders Share Hard-Won Strategies to Reduce Antipsychotic Use, Rehospitalizations appeared first on Skilled Nursing News .
You might also wanna read
Optimizing Healthcare Transitions for Prader-Willi Syndrome Patients: A CME Discussion
This article discusses the challenges of transitioning care for patients with Prader-Willi syndrome (PWS) from pediatric to adult healthcare
States target private equity-owned nursing homes after safety crises, with Connecticut leading on transparency laws
The article examines how states are increasingly targeting private equity's role in nursing homes following a series of crises. It highlight

Florida mental health leader applauds Speaker-designate Garrison's commitment to behavioral health as top priority
Dr. Christine Cauffield, CEO of LSF Health Systems, praises Florida House Speaker-designate Sam Garrison for prioritizing mental health as a
newsbeep.com·1mo agoDra. Sacramento Pinazo: Les cooperatives de cures com a canvi estructural en l'atenció a la gent gran
La doctora Sacramento Pinazo-Hernandis, experta en gerontologia i envelliment, defensa en aquesta entrevista/anàlisi que les cooperatives de
A Rural Solution to the Geriatric Mental Health Crisis
aha.org·15d ago
Real Solutions to Workplace Violence
aha.org·1mo ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.